The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZBIO | +60.66% | N/A | N/A | +79% |
| S&P | +12.65% | +91.73% | +13.89% | +20% |
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.01M | 65.7% |
| Gross Margin | 99.77% | 0.0% |
| Market Cap | $405.37M | 0.0% |
| Market Cap / Employee | $3.12M | 0.0% |
| Employees | 130 | 0.0% |
| Net Income | -$52.22M | -37.5% |
| EBITDA | -$55.15M | -39.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $44.01M | -76.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.22M | 1435.7% |
| Short Term Debt | $0.79M | 60.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -71.80% | 0.0% |
| Return On Invested Capital | -126.07% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$41.74M | -34.7% |
| Operating Free Cash Flow | -$41.74M | -34.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.97 | 1.39 | 1.06 | 1.43 | - |
| Price to Sales | 68.46 | 22.02 | 27.05 | - | |
| Price to Tangible Book Value | 1.97 | 1.39 | 1.06 | 1.43 | - |
| Enterprise Value to EBITDA | -7.83 | 0.14 | -0.51 | -2.42 | - |
| Return on Equity | -115.5% | -88.4% | - | ||
| Total Debt | $0.38M | $1.00M | $1.23M | $1.01M | 98.43% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
